AUS
NZ
UK
CA
USA
IND
Highlights:
- Amarin Corporation is a pharmaceutical company with a market capitalization of $226.61 million.
- The stock shows a negative price-to-earnings ratio of -6.13.
- The stock price has ranged between a twelve-month low of $0.43 and a high of $1.37.
Amarin Corporation (NASDAQ:AMRN) operates within the pharmaceutical sector, focusing on the development and commercialization of therapeutics for cardiovascular conditions. This sector is known for its high level of research, stringent regulatory requirements, and reliance on scientific breakthroughs to introduce new products.
Stock Performance and Price Fluctuations
The stock of Amarin opened at $0.55 on the most recent Monday. Over the past twelve months, the stock has experienced significant fluctuations, with its lowest value reaching $0.43 and its highest value peaking at $1.37. These price movements are influenced by a variety of factors, such as developments in clinical trials, market conditions, and regulatory decisions within the pharmaceutical industry.
Market Metrics
Amarin has a market capitalization of $226.61 million, reflecting the company's standing within the pharmaceutical industry. Its negative price-to-earnings ratio of -6.13 indicates that the company is currently reporting losses. This is a typical scenario for companies in the pharmaceutical sector, particularly those engaged in lengthy product development processes. The company’s beta of 1.82 suggests higher volatility relative to the broader market, common for pharmaceutical companies, which can experience large swings in stock price due to news or product developments.
Moving Averages
Amarin's stock is currently trading with a 50-day simple moving average of $0.51 and a 200-day simple moving average of $0.60. These moving averages are used to gauge the general trend of the stock over time, smoothing out short-term fluctuations. A lower 50-day average compared to the 200-day average may suggest that the stock is in a bearish phase.
Amarin's stock performance reflects the challenges of operating in the pharmaceutical sector, where price fluctuations are often driven by regulatory approvals, market reactions to clinical trial results, and competitive pressures. The negative price-to-earnings ratio and the volatility indicated by the company's beta are consistent with trends often observed in pharmaceutical firms that are still in the development phase of their products.
